Literature DB >> 32133566

Differentially expressed lncRNAs in peripheral blood mononuclear cells from middle-aged female patients with rheumatoid arthritis-associated interstitial lung disease.

Wei Zhou1,2, Juan Zheng3, Min Yuan2, Lindong Yuan4, Xiaodong Jia3, Huaxiang Liu5.   

Abstract

OBJECTIVES: Interstitial lung disease (ILD) is frequently associated with rheumatoid arthritis (RA) and has a large impact on the prognosis of RA, particularly among females, with an increased prevalence and severity compared with that of males. Here, we aimed to investigate the lncRNA profiles in peripheral blood mononuclear cells (PBMCs) from middle-aged female patients with RA-ILD to determine whether they could help diagnose RA-ILD.
METHOD: We collected PBMCs from middle-aged female healthy controls, and RA and RA-ILD patients, excluding those with known risk factors of RA-ILD, such as being elderly or male, smoking, and having a history of other diseases. Then, a microarray analysis was applied to profile the lncRNA and mRNA levels in 3 pairs of samples. qPCR was performed to evaluate the candidate lncRNAs from 20 participants of each group.
RESULTS: The expression levels of NR_002819, NR_038935, and ENST00000603415 were significantly increased in the RA-ILD group, while the expression level of ENST00000560199 was significantly decreased. As risk factors for RA-ILD, the area under the curve (AUC) values of NR_002819, NR_038935, and ENST00000603415 were 0.858, 0.704 (medium diagnostic accuracy), and 0.976 (high diagnostic accuracy), respectively. As a protective factor for RA-ILD, the AUC of ENST00000560199 was 0.853(medium diagnostic accuracy).
CONCLUSIONS: To the best of our knowledge, this is the first study of lncRNA profiles in RA-ILD. The expression levels of NR_002819 (MALAT1), NR_038935, ENST00000603415, and ENST00000560199 were significantly different in the RA-ILD group and could be potential biomarkers for the assessment and diagnosis of middle-aged female RA-ILD patients. Key Points • The expression profile of lncRNAs in PBMCs from RA-ILD patients was evaluated. • NR_002819, NR_038935, and ENST00000603415 increased in RA-ILD patients. •ENST00000560199 decreased in RA-ILD patients. • The 4 lncRNAs might be potential biomarkers for diagnosis of RA-ILD.

Entities:  

Keywords:  Biological marker; Interstitial lung disease; Rheumatoid arthritis; lncRNA

Mesh:

Substances:

Year:  2020        PMID: 32133566     DOI: 10.1007/s10067-020-04977-w

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  38 in total

1.  Risk factors for progression and prognosis of rheumatoid arthritis-associated interstitial lung disease: single center study with a large sample of Chinese population.

Authors:  Qiang Fu; Li Wang; Luling Li; Yifan Li; Ran Liu; Yi Zheng
Journal:  Clin Rheumatol       Date:  2018-12-07       Impact factor: 2.980

2.  Breathing New Life into Interstitial Lung Disease in Rheumatoid Arthritis.

Authors:  Peter K Gregersen; Ellen M Gravallese
Journal:  N Engl J Med       Date:  2018-10-20       Impact factor: 91.245

3.  The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.

Authors:  Julie Morisset; Eric Vittinghoff; Bo Young Lee; Roberto Tonelli; Xiaowen Hu; Brett M Elicker; Jay H Ryu; Kirk D Jones; Stefania Cerri; Andreina Manfredi; Marco Sebastiani; Andrew J Gross; Brett Ley; Paul J Wolters; Talmadge E King; Dong Soon Kim; Harold R Collard; Joyce S Lee
Journal:  Respir Med       Date:  2017-04-22       Impact factor: 3.415

4.  Understanding the determinants of health-related quality of life in rheumatoid arthritis-associated interstitial lung disease.

Authors:  Jake G Natalini; Jeff J Swigris; Julie Morisset; Brett M Elicker; Kirk D Jones; Aryeh Fischer; Harold R Collard; Joyce S Lee
Journal:  Respir Med       Date:  2017-04-05       Impact factor: 3.415

5.  Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis.

Authors:  Carl Turesson; W Michael O'Fallon; Cynthia S Crowson; Sherine E Gabriel; Eric L Matteson
Journal:  J Rheumatol       Date:  2002-01       Impact factor: 4.666

6.  Rheumatoid Arthritis-Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs and Mortality.

Authors:  Karina Raimundo; Joshua J Solomon; Amy L Olson; Amanda M Kong; Ashley L Cole; Aryeh Fischer; Jeffrey J Swigris
Journal:  J Rheumatol       Date:  2018-11-15       Impact factor: 4.666

Review 7.  Reinterpreting Evidence of Rheumatoid Arthritis-Associated Interstitial Lung Disease to Understand Etiology.

Authors:  Emily K Wu; Robert D Ambrosini; R Matthew Kottmann; Christopher T Ritchlin; Edward M Schwarz; Homaira Rahimi
Journal:  Curr Rheumatol Rev       Date:  2019

8.  Rheumatoid arthritis-interstitial lung disease-associated mortality.

Authors:  Amy L Olson; Jeffrey J Swigris; David B Sprunger; Aryeh Fischer; Evans R Fernandez-Perez; Josh Solomon; James Murphy; Marc Cohen; Ganesh Raghu; Kevin K Brown
Journal:  Am J Respir Crit Care Med       Date:  2010-09-17       Impact factor: 21.405

Review 9.  Up-to-Date Information on Rheumatoid Arthritis-Associated Interstitial Lung Disease.

Authors:  Takafumi Suda
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2016-05-31

10.  Predicting outcomes in rheumatoid arthritis related interstitial lung disease.

Authors:  Joseph Jacob; Nikhil Hirani; Coline H M van Moorsel; Srinivasan Rajagopalan; John T Murchison; Hendrik W van Es; Brian J Bartholmai; Frouke T van Beek; Marjolijn H L Struik; Gareth A Stewart; Maria Kokosi; Ryoko Egashira; Anne Laure Brun; Gary Cross; Joseph Barnett; Anand Devaraj; George Margaritopoulos; Ronald Karwoski; Elisabetta Renzoni; Toby M Maher; Athol U Wells
Journal:  Eur Respir J       Date:  2019-01-03       Impact factor: 16.671

View more
  1 in total

1.  The clinical efficacy of traditional Chinese medicine in the treatment of rheumatoid arthritis with interstitial lung disease: A protocol of systematic review and meta-analysis.

Authors:  Zhaoyi Liu; Jie Shen; Zhouli Shen; Dongyi He
Journal:  Medicine (Baltimore)       Date:  2020-10-09       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.